There is now substantial evidence that soluble oligomers are primary toxic agents in amyloid diseases. Development of an antibody recognizing the toxic soluble oligomeric forms of different and unrelated amyloid species suggests a common conformational intermediate during amyloidogenesis. We previously observed common occurrence of a novel secondary structure element, which we call -sheet, in molecular dynamics simulations of various amyloidogenic proteins, and we hypothesized that the toxic conformer is comprised of -sheet structure. As such, -sheet may represent a conformational signature of the misfolded intermediates of amyloidogenesis and a potential unique binding target for peptide inhibitors. Recently, we reported the design and characterization of a novel hairpin peptide (1 or AP90) that adopts stable -sheet structure and inhibits the aggregation of the -Amyloid Peptide A42, and transthyretin. AP90 is a 23-residue hairpin peptide featuring alternating D-and L-amino acids with favorable conformational propensities for -sheet formation, and a designed turn. For this study, we reverse engineered AP90 to identify which of its design features is most responsible for conferring -sheet stability and inhibitory activity. We present experimental characterization (CD and FTIR) of 7 peptides designed to accomplish this. In addition, we measured their ability to inhibit aggregation in three unrelated amyloid species: A42, transthyretin, and human islet amylin polypeptide. We found that a hairpin peptide featuring alternating L-and D-amino acids, independent of sequence, is sufficient for conferring -sheet structure and inhibition of aggregation. Additionally, we show a correlation between -sheet structural stability and inhibitory activity.
Introduction
Over 40 distinct human amyloid diseases have been identified, many of which contribute to severe neurodegeneration and organ dysfunction [1] . Amyloid diseases are associated with the aggregation of normally-soluble peptides or proteins to insoluble, -rich amyloid deposits [2, 3] .
Multiple aggregation pathways are thought to be available to amyloidogenic species, with different pathways furnishing multiple distinct conformational intermediates [4] [5] [6] . The mechanism of amyloid assembly and its associated pathology are not well understood; however, there is substantial experimental evidence that the soluble oligomeric intermediates populated during amyloidosis are the primary species responsible for cellular toxicity [7] [8] [9] [10] .
The development of conformation-specific antibodies recognizing the toxic oligomeric intermediates of many different amyloid peptides and proteins suggests a common backbone structure associated with amyloidogenic intermediates [11, 12] ; this is supported by the crossreactivity of different, unrelated amyloid proteins and peptides [13] [14] [15] [16] [17] . Proposed amyloid oligomer models in the literature are widely variant, including helix-containing assemblies [18, 19] , extended -sheets resembling small fibrillar structures [20] , -barrels [21] [22] [23] [24] , looselystructured assemblies [25] , and spiraling sheets [26] ; the apparent availability of multiple aggregation pathways allows for structurally and compositionally diverse intermediates, each associated with one of many aggregation pathways. Notably, NMR experiments do not detect -sheet or -helix structure in toxic A (Amyloid -peptide residues 1-42) pentamers and hexamers [25] , a finding corroborated by the absence of -sheet or -helix fingerprints in CD spectra taken during the lag (or nucleation) phases of polyglutamine, A, islet amylin polypeptide (IAPP), and -synuclein aggregation [27] [28] [29] [30] [31] [32] . 5 Previous analysis of low-pH molecular dynamics (MD) simulations of the misfolding of various amyloidogenic proteins showed common occurrence of a novel secondary structure called -sheet [33] [34] [35] [36] . -sheet secondary structure is defined by the alternation of  L and  R conformations through sequential amino acid residues, resulting in the parallel alignment of all carbonyl groups and all amide protons on opposite faces of the peptide strand (Fig. 1 ). This alignment of identical functional groups promotes cross-strand hydrogen bonding for sheet-type structure. Based on the shared presence of -sheet structure across these simulations, we proposed that -sheet is a structural signature of the misfolded intermediates of amyloidogenesis, and that -sheet secondary structure might provide a binding target for potential inhibitors of amyloid formation [36] . Our recent studies have demonstrated that designed -sheet peptides (~20 residues) effectively inhibit amyloid formation by binding to toxic oligomeric intermediates [37] . We hypothesize that the mechanism of binding is a backbone-backbone intermolecular interaction between -strand segments. Among these -sheet inhibitors was a 23-residue designed -hairpin named , which we refer to here as AP90 (Fig. 1) . The AP90 design exploits alternating D-and L-C chirality through its -strand segments to stabilize the alternating  L and  R amino acid conformations necessary for -sheet structure. The spectroscopic properties of AP90 have been characterized, and they provide evidence for stable -sheet structure [37] . The CD spectrum of AP90 is relatively featureless, as is expected for a peptide with alternating D-and L-amino acids. Its FTIR spectrum features a strong absorbance peak centered near 1675 cm -1 and a shoulder centered at 1640 cm -1 , both of which match theoretical predictions for -sheet FTIR absorbance [38] . AP90 also gives NH-NH NOESY couplings among amide protons of sequential (i, i+1) residues, indicating the alignment of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   6 successive NH and C=O groups, characteristic of -sheet. Furthermore, AP90 lacks the characteristic signals of -helix and -structure.
In this study, we explored the relative importance of the design features of AP90 in conferring -sheet structure and inhibitory activity against amyloid formation by reverse engineering the peptide. Specifically, we designed peptides that successively eliminate features presumed to stabilize the structure, and we experimentally characterized the spectroscopic properties and inhibitory activity of these resulting peptides. Three amyloidogenic species were chosen to examine general inhibitory activity of the designs: the A42 peptide associated with
Alzheimer's disease [9] , amylin or IAPP associated with type 2 diabetes [39] , and transthyretin (TTR), which is associated with peripheral polyneuropathy and systemic senile amyloidosis [40] .
Aggregation for each of these amyloid species can be monitored by dye-binding assays [41, 42] , allowing quantitation of inhibition against aggregation.
Our study of the AP90 parent and its derivatives revealed that all of the peptides templated to have alternating L-and D-chirality possess inhibitory activity against amyloid formation independent of sequence, although the sequence can modulate the strength of the inhibition. In addition, there is a correlation between -sheet structural stability and activity that supports our hypothesis that -sheet is a structural signature of intermediates during amyloid formation.
Results and Discussion
Deconstructing determinants of inhibition 7 Our initial interest was in determining which of AP90's design features were most responsible for both stabilizing -sheet secondary structure and conferring inhibitory activity in amyloidogenic systems. The AP90 design was constructed from a 23-residue hairpin template featuring two -strands joined by a central turn. The template contains D chirality at the C of strand residues 4, 6, 8, 16, 18 , and 20 ( Fig. 1 ). This sequence template is referred to henceforth as the "L/D template." In an attempt to optimize stability, AP's strand segments are composed of amino acids with favorable propensities for either the  L or  R conformations [43, 44] .
Additionally, AP90 features a 5-residue designed turn (-NEYSG-) [34] to promote cross-strand hydrogen bonding. The N-and C-termini of AP90 are capped with Ac-RG-or -GR-NH 2 ,
respectively, for improved solubility [45] . Solubility is a particularly important concern for side chain selection as well, because aggregation is critical to toxicity and we want to ensure that our -sheet designs are nontoxic.
The peptides reported here were designed to study the contributions of these various sequence elements of the AP90 parent design to -hairpin structure and inhibitory activity. The particular elements selected for study include: the presence of a designed turn; amino acid conformational propensity; and, the L/D template. For our design process, we proceeded from the assumption that the AP90 peptide represents an optimized design. Our sequential design modifications to this parent sequence used sequence randomization through the L/D template of AP90 to successively eliminate the peptide's design features and, presumably, destabilize -sheet structure. Our expectation was that increasing destabilization would be confirmed and monitored by reduced inhibitory activity and changes in predicted spectroscopic hallmarks.
Modifications gradually decreased sequence similarity to the AP90 parent, an effect we represented using sequence identity relative to AP90. The designs are listed in assigned to one of two groups: peptides that follow the L/D template ("templated" designs) and peptides that do not ("non-templated" designs). They are ordered according to sequence identity relative to AP90.
Main chain structure responsible for inhibition independent of sequence
Inhibition experiments were used to study which of AP90's design features confer general inhibitory activity. Inhibitory activity was measured by co-incubating peptide designs with each of the amyloid species A42, IAPP, and TTR at suitable conditions for in vitro aggregation; aggregation was then quantitated by a dye-binding assay using either Thioflavin T (ThT) fluorescence (A42 and IAPP) or Congo Red (CR) absorbance (TTR). Unfortunately, the inability to apply a single dye-binding assay to several different amyloidogenic species is a recurring problem in the relevant literature [45, 46] .
We have previously shown that the AP90 lead compound is an inhibitor of A42 and TTR aggregation at conditions similar to those reported here. Under the assay conditions used for this study, AP90 nearly completely abolished A42 aggregation when co-incubated at 4-fold excess (Fig. 2a , Table 2 ). Co-incubation of AP90 with IAPP at an 8-fold excess resulted in 83% inhibition of aggregation (Table 2 ). Co-incubation of AP90 with TTR at a 10-fold excess resulted in 65% inhibition of aggregation ( Table 2 ). All modified designs were evaluated relative to the parent AP90. Representative traces for inhibition experiments involving all designs are included in Figure 2 and the average inhibition values and associated error over 3 independent trials are provided in Table 2 .
For our first design modification, we scrambled the sequence (retaining the amino acid composition) through AP90's -strand segments (residues 3-9 and 15-21) while maintaining the 9 L/D template, RG tails, and designed turn (Fig.1) . The resulting derivative (AP5) had 100% retention of sequence composition and chirality but only 65% sequence identity relative to AP90, and it demonstrated nearly identical inhibitory activity against A42 and improved inhibition against IAPP, with activity against TTR reduced to 37% inhibition (Table 2 ). However, because AP90's -strand residues all possess favorable conformational propensities, scrambling only through strand segments likely produced little destabilization. That scrambling the strand sequences did not affect inhibitory potency demonstrates that the sequence per se is not determining activity -the same inhibitory effect is achieved with an alternate amino acid order.
To both remove any stabilizing effect of the designed turn and introduce amino acids lacking high -sheet propensity into the strand segments, we next scrambled the sequence through both strands and the turn (residues 3-21), while again maintaining the L/D template and RG tails. This yielded a peptide (AP6) with only 25% sequence identity to the parent AP90.
Co-incubation of AP6 with amyloid species gave 35% inhibition against A42 and 75% inhibition of IAPP, thereby displaying significantly reduced activity due to the loss of the designed turn relative to both AP90and AP5 (Table 2 ). AP6 interfered with Congo Red binding to TTR, preventing quantitation of its inhibition of TTR amyloidosis using the CR-binding assay.
Unfortunately, several subsequent designs were similarly unsuitable for the Congo Red binding assay, and they had to be evaluated by an alternative method, as discussed further below.
To further test the apparent resilience of the L/D template in conferring inhibitory activity, we randomly selected amino acids for all 23 residues while maintaining the L/D template. This design choice was intended to decouple effects due to the L/D template from any composition-specific effects. Random selection yielded two designs (AP3 and AP4) with less 10 than 20% sequence identity to AP90. Neither design showed uniformly high inhibition across all systems studied: AP3 inhibited 36% of the IAPP aggregation but only 11% of the A42 aggregation ( Table 2 ). AP4 inhibited 42% of the A42 aggregation and 11% of IAPP aggregation ( Table 2 ). Like AP6, both AP3 and AP4 were unsuitable for the CR-binding assay due to interference with the dye.
Two additional peptides were designed without the L/D template: P2 is a scramble of the AP90 parent sequence that does not enforce alternating L-and D-chirality through strand segments, while P90 is an all-L-amino acid analog of AP90( Table 1 ). The non-templated, scrambled AP90 sequence, P2, was inactive against both A42 and IAPP aggregation ( Table 2) .
Like several of the other designs, P2 bound Congo Red so that the TTR assay could not be performed and only inhibition of A42 and IAPP aggregation could be measured. The inactivity of P2 demonstrates the necessity of the L/D template for conferring inhibitory activity.
Additionally, it shows that the absolute amino acid composition of AP90, AP5, AP6, and P2 (all 100%) is not responsible for activity, as all of the L/D template peptides inhibit amyloid formation to some degree while a peptide utilizing the same amino acids as AP90, AP5 and AP6 but lacking the L/D template does not. This also shows that it is not the D-amino acids per se that are responsible for inhibition in the templated designs.
Eliminating D-chirality from the AP90 sequence resulted in a completely insoluble peptide (P90) despite the unchanged isoelectric point and side chains (relative to AP90). Due to this lack of solubility, inhibition experiments could not be performed with P90. Note that the AP90 and P90 peptides contain exactly the same chemical sequence but 6 of the residues in 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 AP90 have D-chirality to impose templating of the -sheet structure ( Table 1) . The difference in the behavior of AP90 and P90 is striking.
Unfortunately the inhibition (or lack thereof) of TTR could not be evaluated for many of the designs due to their binding to Congo Red. Consequently we also evaluated the compounds in a more qualitative binding assay involving immobilization of the designs to agarose beads and then determining whether they preferentially bind pre-incubated toxic TTR samples, as described earlier [37] . We have previously shown that AP90 preferentially binds toxic but not nontoxic solutions of A42 and TTR [37] , consistent with our -sheet hypothesis. In line with the A42 and IAPP inhibition results, the L/D templated designs all bind species from the pre-incubated toxic TTR solutions while the non-templated designs do not, and in this case P90 could also be evaluated because its self-aggregation is controlled through immobilization on the beads (Fig. 3 , Table 2 ).
Successive elimination of design features resulted in a decrease in binding to the toxic oligomeric species as probed by the agarose bead binding experiment with TTR or as reflected in the inhibition of fibril formation by binding of the oligomeric precursor to the fibrillar state. This decrease correlated with decreasing sequence identity relative to AP90 (Fig. 4) , confirming the predicted effects of our design modifications. Despite our sequence modifications, however, we were unable to fully quench inhibition by the L/D templated peptides, as both the completely randomized designs, AP3 and AP4, inhibited amyloid aggregation and/or preferentially bound the TTR toxic oligmers. Our inability to abolish inhibition suggests that the L/D chirality template is predominantly responsible for conferring inhibitory activity to our designs, rather than the nature of the side chains, the absolute composition, or the designed turn. Even without a well-designed turn or residues with high propensity to form -strands, the L/D template confers 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 meaningful inhibitory activity and the ability to distinguish between nontoxic and toxic conformers. Consequently, the L/D template appears to be a novel structural template for design of general inhibitors of amyloidosis whose mechanism of inhibition appears to be distinct from any previously reported peptides or organic molecules.
Destabilization of -sheet structure lowers inhibition
In order to assess the structural effects of our design modifications, CD spectra were recorded for all peptides (Fig. 4a) . Due to the variable solubility and to ensure solubility of all designs and uniformity of solution conditions, all CD spectra were taken in phosphate buffer with 50% acetonitrile (v/v). The presence of acetonitrile did not significantly affect the CD spectra of the very soluble compounds and allowed us to record the spectra of non-templated designs that are not as soluble under aqueous conditions. Featureless spectra were anticipated for peptides including alternating L-and D-amino acids due to the opposite absorption of circularly polarized light [37] . A CD signal near 195 nm is typically attributed to unstructured conformers, often being referred to as the 'random coil' signal, and if it is due to the L-amino acids the signal is negative and positive for D-amino acids.
We have therefore interpreted larger negative signals near 195 nm as being due to distortions of the turn and fraying of the ends of the hairpin upon modification, as both of these regions are comprised of L-amino acids. Furthermore, the coupling of a single chiral C and N-terminal peptide bond is sufficient for production of a CD minimum near 200 nm [48] . So, while a negative signal in this region is typically taken to represent "random coil", it is potentially more complicated involving dynamic exchange between many non-random conformers, particularly after loss of the turn. As such, we take a more negative minimum near 195-200 nm to reflect a 13 change in the dynamics and structure away from the AP90 state without being able to precisely describe the detailed nature of the changes.
In any case, the first of our design modifications involving shuffling of the residues in the strands (AP5) resulted in a CD spectrum very similar to that of AP90, each with a relatively featureless, flat region between 210-260 nm and a minimum near 195 nm (Fig. 4a) . In the spectrum of AP6, which is due to shuffling of the strands and the turn residues, there is a broad shoulder centered at roughly 215 nm (extending to 225 nm) that suggests the possibility of some (Table 3) , indicating increasing random coil character among their L-amino acids.  min is strongest in the spectra of AP3 and AP4, the two peptides expected to possess the lowest -sheet stability.  min also red-shifted among templated peptides with sequentially destabilizing modifications, possibly due to contributions of -helix and -sheet conformations transiently populated by the destabilized peptide in the L-amino acid stretch [37] . Surprisingly, the CD spectrum for the scrambled design P2 is very similar to that of AP90. We expected a stronger minimum near 195 nm. Regardless, P2's inactivity as an inhibitor 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 suggests an absence of any structural feature -such as -or -sheet -that could confer activity.
The CD spectrum of the all-L peptide P90 reflects weak -sheet structure (Fig. 4a) .
To further characterize sequence effects on structure, we recorded solid-state FTIR absorbance spectra for all AP90 derivatives (Fig. 4b) . sheet secondary structure produces FTIR bands that are distinct from characteristic -sheet and -helix bands [38] . The FTIR absorbance spectrum for AP90 features a dominant peak at 1675 cm -1 , with a shoulder centered at roughly 1640 cm -1 ; notably, these are the predicted features for -sheet absorbance spectra [38] . AP5, AP3, and AP4 gave dominant peaks at either 1640 or 1675 cm -1 , suggesting that there are subtle differences in the -sheet structures. The FTIR absorbance spectra of AP4 and AP5 feature a broad band centered at 1640 cm -1 . AP6 stands out with a dominant peak centered at 1620 cm -1 in the spectral region typically associated with -sheet, and a broad shoulder near 1660 cm -1 . In the past, we have found that the drying process required for the solid-state FTIR measurements can sometimes induce -structure, an effect that might be at play here in the 7-residue segment of L-amino acids in AP6.
The non-templated sequence P2 gave a narrow absorbance band centered near 1690 cm
with a shoulder near 1710 cm -1 . The all-L-amino acid P90 showed a dominant FTIR band near 1620 cm -1 in the region associated with -sheet, with a broad, weak shoulder at 1660 cm -1 . P90's sequence includes a designed turn and several residues with high -propensity, supporting FTIR identification of -hairpin structure, consistent with its CD.
We have previously hypothesized that -sheet secondary structure represents a conformational signature of toxic intermediates of amyloidosis [33] [34] [35] [36] . Low-pH MD simulations provided the initial basis for this hypothesis, and subsequent design and 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 15 experimental characterization of -sheet inhibitors of amyloidosis have supported our assertion [37] . Under the assumption that -sheet is a structural feature common to oligomeric intermediates, stable -hairpins were expected to inhibit amyloid formation in all three amyloid systems studied (A42, IAPP, and TTR) through backbone/backbone interactions between -sheet/strand segments. Because of the nature of this proposed inhibitory mechanism, a correlation between -hairpin structural stability and general inhibitory activity is expected. Although the non-templated design P90 was expected to be an inactive, unstructured control, it contained -character as evidenced by CD and FTIR (Fig. 4b) . Inhibition results could not be obtained for P90 because it is insoluble in our aqueous assay conditions; however, it does not bind the toxic oligomer species of TTR, and instead preferentially binds native tetrameric 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 16 TTR (Fig. 3) . We have shown that a designed trpzip -hairpin can inhibit TTR aggregation by binding to the native tetramer, while other -hairpins do not [37, 52] . -hairpins are also known inhibitors of A by binding the monomer, so it is possible P90 could inhibit aggregation, but it is far too insoluble and it would do so by a different mechanism than the templated L/D designs Nevertheless, the complete loss of solubility caused solely by the design's elimination of Dchirality further reflects a substantial structural change. This structural change associated with elimination of D-chirality demonstrates the remarkable effect of the L/D template.
Conclusions
Our results identify a new sequence template for -sheet peptide inhibitors of amyloidosis. Additionally, the apparent correlation between -sheet stability and inhibitory potency in our templated peptides supports an inhibitory mechanism featuring backbone/backbone interactions among -strand segments. The growing evidence for the association of -sheet with amyloidogenic intermediates identifies a new target for inhibitors of amyloidosis. Considering that we are only now characterizing the spectroscopic properties and inhibitory activity of -sheet peptides, we have much room for further optimization of both stability and activity. Future designs are expected to possess even higher inhibitory potency as we further inform our design process. Looking forward, potential therapeutic peptides following an L/D template could have an advantage in in vivo studies, as they should not be metabolized as rapidly as their all-L analogs. In addition, to further optimize our designs for inhibitory activity, we are now exploiting our proposed inhibitory mechanism to develop diagnostic assays for binding toxic oligomeric species from solution, and which may also aid in structural characterization of the toxic oligomers.
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Materials and Methods
Materials
Designed peptides were purchased from CPC Scientific or American Peptide Company (APC) and supplied as ≥95% purity as assessed by RP-HPLC and mass spectrometry. A42 and IAPP were also purchased from APC. Lyophilized A42 and IAPP were treated with 1,1,1,3,3 
Solution Aggregation Assays
A42 was thawed from -18° C and re-treated in HFIP for 30 min. The HFIP was then removed under gentle air, and the resulting dry peptide was further exsiccated 30 min in a Thermo Scientific Savant SC110A SpeedVac. HFIP-treated A42 was dissolved to 0.75 mg/mL in 6 mM NaOH by sonication (5 min). The 0.75 mg/mL stock was filtered through a 0.22 m Costar Spin-X cellulose centrifuge filter, and its concentration was verified by UV/Vis absorbance at 220 nm ( 220 =50,000 M -1 cm -1 ) using a Thermo Scientific NanoDrop 2000 spectrometer [49] . The stock was allowed to rest 4 hr at room temperature (RT) for NaOH treatment; aliquots were then portioned into wells of a Nunc 96-well fluorescence plate and diluted to 10 M A42 with PBS (11 mM phos, 152 mM NaCl, 3 mM KCl, 22 M ThT, pH 7.4) containing inhibitor peptide (inhibitor concentrations verified by Trp/Tyr UV/Vis abs at 280 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 18 nm). In the case of the less soluble AP6 and P2 peptides, 0.9% DMSO was added. Plates were sealed and incubated away from light at RT. RT was chosen over 37° C because high temperatures are thought to favor fibril elongation over oligomerization for this system, and the oligomer is our intended binding target [50] . AFM imaging confirmed the presence of relatively short (rather than long) fibrils following incubation of A42 at the conditions detailed above (not shown).
Dry IAPP was thawed from -18° C and treated with HFIP, as described above. The HFIPtreated IAPP was dissolved to 1 mg/mL in DMSO. 1 mg/mL stock aliquots were portioned into wells of a 96-well fluorescence plate and diluted to 10 M nominal IAPP concentration with PBS (11 mM phos, 152 mM NaCl, 3 mM KCl, 22 M ThT, pH 7.4) containing inhibitor peptide (inhibitor concentrations verified by Trp/Tyr UV/Vis abs at 280 nm). Plates were then sealed and incubated at 37º C. The ThT fluorescence assay was carried out as described above.
Dry TTR was thawed from -18º C and dissolved directly to 10 M TTR (40 M monomer) in either low-pH acetate buffer (50 mM NaOAc, 100 mM KCl, 1 mM EDTA, pH 4.5)
or neutral-pH PBS (11 mM phos, 152 mM NaCl, 3 mM KCl, pH 7.4) containing inhibitor peptide. Samples were incubated at either 4º (neutral pH) or 37º C.
ThT Fluorescence Assay
For the ThT fluorescence assay, plates were removed from incubation and read once per timepoint in a Tecan Safire 2 plate reader ( ex =450 nm,  em =480 nm). Plates were shaken prior to the initial ("t = 0") timepoint, but not prior to any subsequent timepoints. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   19 For the CR-binding assay, three 10 L sample aliquots were each combined with 190 L of a 10 M CR solution made in PBS (11 mM phos, 152 mM NaCl, 3 mM KCl, pH 7.4) in wells of a 96-well clear micro-plate (Falcon). The plate was then read for absorbance at 477 nm and 540 nm, and CR binding was determined according to a previously published equation [37] .
Congo Red Binding Assay
Transthyretin Column Binding Assay
Peptide designs were immobilized to the Pierce Amino Link resin following the manufacturer's instructions. Coupling and all further steps and analyses have been described by Hopping et al. [37] . Fresh, tetrameric TTR at neutral pH and pre-incubated toxic solutions of TTR at low pH (toxicity confirmed through cell-based assays using neuroblastoma cells) were prepared and applied to the column. Bound material was eluted with guanidine hydrochloride and analyzed by dot blot analysis. The difference between the binding of the toxic and nontoxic solutions was determined for each peptide, except AP3, which lacks a lysine and the N-terminus is acetylated preventing its coupling to the resin.
Circular Dichroism Spectroscopy
Dry peptide was dissolved to 90 M in 50/50 -AcCN/PB (10 mM phosphate, pH 7.4).
Concentrations were verified by Trp/Tyr UV/Vis absorbance. CD spectra were taken at 25° C on an Aviv model 420 spectrometer (Aviv Biomedical). The dynode voltage was monitored to ensure it was below 500 volts. Average values from 3 scans were plotted using the Origin 8 software (Originlab, Northhampton, MA). All spectra were smoothed using the Savitsky-Golay method with 5-12 points/window and polynomial order 2. The smoothed data were subtracted from the raw data and the differences were minimal and evenly distributed around zero. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 20
Fourier Transform Infrared Spectroscopy
FTIR spectroscopy assays were carried out according to the method described by Hopping et al. without any deviations [37] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   22 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 24 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 25 Negative CD in this region is typically considered a reflection of lack of structure, often referred to as random coil. Sequence identity and composition relative to AP90 are reiterated to compare decreasing  min with increasing randomness-of-design .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 26 highlighted in either yellow, blue, or red were subject to modification for design of specific peptides. The highlighting on the structure illustrates which sequence segments were modified for each design, and they are color matched with Table 1 . Also see Table 1 for specific sequences. The image was generated using UCSF Chimera [51] . 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 27 Fig. 3 . Difference between binding of toxic versus nontoxic solutions of TTR. Peptides were immobilized on agarose beads and either fresh TTR at neutral pH was applied or TTR incubated at low pH. Toxicity was assayed using SH-SY5Y neuroblastoma cells, as described earlier [37] . 
Figure Legends
AP90
Ac-RGEmNlSwMNEYSGWtMnLkMGR-NH 2 100 100 100 Parent design
AP5
Ac-RGNwNeSkMNEYSGWmLmLtMGR-NH 2 65 100 100
Scrambled a-strand sequences of AP90 (residues 3-9 and 15-21)
AP6
Ac-RGEaWmYlKNNLSETmMsNmWGR-NH 2 25 100 100
Scrambled sequences through a-strands and turn of AP90 (residues 3-21) Table 1 Table
AP3
